- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05400317
A Study to Evaluate the Efficacy and Safety of AD-218
January 29, 2024 updated by: Addpharma Inc.
A Randomized, Double-blinded, Active-controlled, Multicenter Phase 3 Clinical Trial and Open-label, Extension Study to Evaluate the Efficacy and Safety of AD-218 in Patients With Mixed Dyslipidemia
The purpose of this study is to evaluate the efficacy and safety of AD-218
Study Overview
Detailed Description
Condition or disease : Mixed Dyslipidemia Treatment Drug : AD-218, AD-218A, Placebo of AD-218, Placebo of AD-218A
Study Type
Interventional
Enrollment (Estimated)
520
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Sarah Yoon
- Phone Number: 82-031-891-5576
- Email: sryoon@addpharma.co.kr
Study Contact Backup
- Name: Kyu Chang Won, M.D., Ph.D
Study Locations
-
-
Nam-gu
-
Daegu, Nam-gu, Korea, Republic of, 42415
- Recruiting
- Yeongnam University Hospital
-
Contact:
- Kyu Chang Won, M.D., Ph.D
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- A man or woman over 19 years old.
- Sign on ICF prior to study participation
Exclusion Criteria:
- History of Fibromyalgia, Myopathy etc (CK ≥ 2 X ULN)
- Other exclusions applied
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Active Comparator : Test group
AD-218
|
PO, Once daily(QD), 12weeks
|
Active Comparator: Active Comparator : Control group
AD-218A
|
PO, Once daily(QD), 12weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent change (%) of non-HDL-C from baseline at week 12
Time Frame: from baseline at 12 weeks
|
non-HDL-C at week 12 compared AD-218 with AD-218A
|
from baseline at 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent change (%) of non-HDL-C from baseline at week 4, 8
Time Frame: from baseline at week 4,8
|
non-HDL-C at week 4,8 compared AD-218 with AD-218A
|
from baseline at week 4,8
|
Percent change (%) of Lipid panel from baseline at week 4, 8, 12
Time Frame: from baseline at week 4, 8, 12
|
Lipid panel at week 4, 8, 12 compared AD-218 with AD-218A
|
from baseline at week 4, 8, 12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Kyu Chang Won, M.D., Ph.D, Yeungnam University Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 27, 2022
Primary Completion (Estimated)
March 31, 2025
Study Completion (Estimated)
June 30, 2025
Study Registration Dates
First Submitted
May 27, 2022
First Submitted That Met QC Criteria
May 27, 2022
First Posted (Actual)
June 1, 2022
Study Record Updates
Last Update Posted (Estimated)
January 31, 2024
Last Update Submitted That Met QC Criteria
January 29, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AD-218P3
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mixed Dyslipidemia
-
University of GuadalajaraCompleted
-
AbbottCompletedMixed DyslipidemiaUnited States
-
Hanlim Pharm. Co., Ltd.RecruitingMixed DyslipidemiaKorea, Republic of
-
IlDong Pharmaceutical Co LtdNot yet recruiting
-
Arrowhead PharmaceuticalsCompletedMixed DyslipidemiaUnited States, Australia, Poland, New Zealand, Canada, Hungary
-
Provident Clinical ResearchReliant PharmaceuticalsCompleted
-
Arrowhead PharmaceuticalsActive, not recruitingMixed DyslipidemiaUnited States, Australia, Canada, New Zealand
-
Provident Clinical ResearchReliant PharmaceuticalsUnknown
-
Kowa Research Institute, Inc.CompletedMixed Dyslipidemia | Primary DyslipidemiaUnited States
-
Merck Sharp & Dohme LLCTerminatedHypercholesterolemia | Mixed Dyslipidemia
Clinical Trials on AD-218
-
AnHeart Therapeutics Inc.Recruiting
-
Simbec ResearchSensorion SACompletedInner Ear Diseases
-
AnHeart Therapeutics Inc.RecruitingIDH1 Inhibitor AB-218 in Patients With Advanced IDH1 Mutant Cholangiocarcinoma and Other Solid TumorCholangiocarcinoma With IDH1 Mutation | Solid Tumors With IDH1 MutationChina
-
Addpharma Inc.CompletedHypertensionKorea, Republic of
-
Addpharma Inc.Recruiting
-
Addpharma Inc.Not yet recruitingHypertension,Essential
-
Addpharma Inc.Completed
-
Addpharma Inc.Not yet recruitingHypertension,EssentialKorea, Republic of
-
Addpharma Inc.CompletedHyperlipidemiasKorea, Republic of
-
Addpharma Inc.Completed